Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
Introduction
Guanylate cyclase C (GC-C), which was originally identified as the receptor for bacterial STa enterotoxin, is a transmembrane receptor with intrinsic guanylate cyclase activity that is predominantly expressed on the luminal surface of intestinal epithelial cells (Schulz et al. 1990). The endogenous peptide hormones guanylin and uroguanylin are GC-C agonists that regulate the guanylate cyclase activity of this receptor. Guanylin and uroguanylin are expressed along the longitudinal axis of the gastrointestinal tract and released into the intestinal lumen, but their expression pattern is distinctly different in major segments of the intestine and in different cell types within the mucosa due to their altered activity in the variable pH microenvironments found at the mucosal surface of the intestine (Wiegand et al., 1992, Li & Goy, 1993, Fan et al., 1996, Hamra et al., 1996, Hamra et al., 1997).
Stimulation of GC-C significantly elevates the intracellular concentration of the second messenger cyclic guanosine-3′, 5′-monophosphate (cGMP), which is involved in the regulation of a broad range of physiological processes, including the activation of cGMP-dependent protein kinase II (PKG-II) (Pfeiffer et al., 1996, Schlossmann et al., 2005). PKG-II phosphorylation regulates the activity of the cystic fibrosis transmembrane conductance regulator (CFTR), an ion channel protein colocalized with PKG-II at the apical surface of intestinal epithelial cells (Seidler et al., 1997, Vaandrager et al., 1998). Thus, the activation of GC-C by guanylin and uroguanylin provides an intrinsic mechanism for the control of intestinal fluid homeostasis. This balance is achieved through the stimulation of transepithelial secretion of chloride (Cl−) and bicarbonate (HCO3−) ions and concomitant inhibition of sodium (Na+) absorption through a blockade of Na+/H+ exchange, which results in decreased Na+ absorption and increased secretion of water into the intestinal lumen (Forte, 1999, Vaandrager, 2002, Sindic & Schlatter, 2006). Studies in GC-C null mice have confirmed the critical role of this receptor in intestinal fluid homeostasis (Mann et al., 1997, Schulz et al., 1997). Thus, the GC-C receptor has the potential as a therapeutic target for the treatment of functional gastrointestinal disorders such as constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
IBS-C and chronic constipation are highly prevalent functional gastrointestinal disorders, which occur more frequently in women than men. IBS-C is characterized by symptoms of chronically recurring abdominal pain, discomfort and bloating in association with symptoms of constipation (Drossman, 2006, Videlock & Chang, 2007). Chronic constipation symptoms include infrequent bowel movements, hard stool, straining during defecation, and a feeling of incomplete evacuation. Abdominal discomfort and bloating may also be present (Sandler & Drossman, 1987, Koch et al., 1997). For both disorders, current therapeutic options are limited. Hence, there is a continued medical need for more effective and safer therapeutic agents.
Linaclotide is an orally active 14-amino acid peptide of the guanylin family of cGMP-regulating peptides that also includes the heat-stable microbial ST peptides. In this study, we have investigated whether the pharmacological properties of linaclotide in both in vitro and in vivo models of gastrointestinal function are mechanistically linked to the activation of GC-C.
Section snippets
Animals
Male and female wild type (wt) and GC-C null (Gucy2c−/−) mice (C57/BL6) were a gift from Mitchell Cohen (Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA). Female CD-1 mice were obtained from Charles River Laboratories (Wilmington, MA). All animal studies were performed in the laboratories of Ironwood Pharmaceuticals and approved by the Institutional Animal Care and Use Committee.
Reagents
Lyophilized linaclotide was obtained from Polypeptide Laboratories, Torrance, CA, USA. Activated
Molecular structure and amino acid sequence of linaclotide
Linaclotide includes several distinct molecular features that provide improved pharmacological properties over those of the endogenous peptide hormones guanylin and uroguanylin. First, the molecular structure of linaclotide is significantly different from those of guanylin and uroguanylin. Specifically, the pharmacologically active conformation of linaclotide is stabilized by three intramolecular disulfide bonds, compared to two such bonds in the endogenous peptides (Fig. 1). Second, the amino
Discussion
Linaclotide is an orally administered 14-amino acid peptide of the guanylin family of cGMP-regulating peptides. Although the pharmacological responses of linaclotide elicited locally in the gastrointestinal tract are related to those of guanylin and uroguanylin, this peptide possesses important structural and pharmacological properties that clearly distinguish it from the endogenous peptide hormones.
The molecular structure and amino acid sequence of linaclotide differ from those of guanylin and
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Acknowledgements
We wish to thank Samuel Rivers for his expert technical assistance in the secretion studies and Carolyn Higgins for her expert support in the analysis of pharmacokinetic studies.
References (28)
The functional gastrointestinal disorders and the Rome III process
Gastroenterology
(2006)- et al.
Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma
Biochemical and Biophysical Research Communications
(1996) Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology
Regulatory Peptides
(1999)- et al.
Mice lacking the guanylate cyclase C receptor are resistant to STa-induced intestinal secretion
Biochemical and Biophysical Research Communications
(1997) - et al.
Guanylyl cyclase is a heat-stable enterotoxin receptor
Cell
(1990) - et al.
Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor
Gastroenterology
(2004) - et al.
Biological and immunological characteristics of 125I-4Tyr and -18Tyr Escherichia coli heat-stable enterotoxin species purified by high-performance liquid chromatography
Analytical Biochemistry
(1985) - et al.
Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment
Gastroenterology Clinics of North America
(2007) - et al.
Rat guanylin cDNA: characterization of the precursor of an endogenous activator of intestinal guanylate cyclase
Biochemical and Biophysical Research Communications
(1992) - et al.
Different segmental transit times in patients with irritable bowel syndrome and “normal” colonic transit time: is there a correlation with symptoms?
Techniques in Coloproctology
(2006)
The molecular target of MD-1100 is guanylate cyclase C (GC-C), an apical receptor on intestinal epithelial cells
Gastroenterology
Identification of two affinity states for low affinity receptors for Escherichia coli heat-stable enterotoxin: correlation of occupation of lower affinity state with guanylate cyclase activation
Molecular Pharmacology
Guanylate cyclase-C-mediated anti-nociceptive effects of linaclotide in rodent models of visceral pain
Neurogastroenterology and Motility
Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity
Proceedings of the National Academy of Sciences USA
Cited by (153)
Broad-spectrum ginsentides are principal bioactives in unraveling the cure-all effects of ginseng
2024, Acta Pharmaceutica Sinica BThe evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics
2024, Journal of Biological ChemistryGuanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain
2022, Trends in Pharmacological SciencesEvaluation and Treatment of Constipation in the Geriatric Population
2021, Clinics in Geriatric Medicine